BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE | A076342 | ANI PHARMACEUTICALS INC
| Petition | Type | Filed | Status | Petitioner |
|---|---|---|---|---|
Amendment to Suitability Petition from Premier Consulting FDA-2024-P-4954 · 9 docket documents Premier Consulting filed an amendment to an ANDA suitability petition (FDA-2024-P-4954) for Benazepril Hydrochloride and Hydrochlorothiazide Oral Liquid, clarifying in response to FDA feedback that the proposed dosage form is a liquid rather than a solution, suspension, or powder for suspension, wit | Suitability | 2024-12-02 | Granted | Premier Consulting |
Source: Regulations.gov. FDA citizen petitions matched by application number.
Highest NADAC/Unit
$0.5443
per ea
Lowest NADAC/Unit
$0.1753
per ea
Brand NDCs
0
Generic NDCs
4
| NDC Description | NADAC/Unit | Unit | Type | Generic NADAC | Effective |
|---|---|---|---|---|---|
| 62559041401BENAZEPRIL-HYDROCHLOROTHIAZIDE 5-6.25 MG TAB | $0.5443 | EA | Generic | — | 2026-02-18 |
| 62559041501BENAZEPRIL-HYDROCHLOROTHIAZIDE 10-12.5 MG TAB | $0.2521 | EA | Generic | — | 2026-06-17 |
| 62559041701BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-25 MG TAB | $0.2378 | EA | Generic | — | 2026-06-17 |
| 62559041601BENAZEPRIL-HYDROCHLOROTHIAZIDE 20-12.5 MG TAB | $0.1753 | EA | Generic | — | 2026-06-17 |
Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.
No patent or exclusivity listings for this strength.